Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Wyeth Merger Would Offer Diversification, Switch Outlet

This article was originally published in The Tan Sheet

Executive Summary

Pfizer's potential acquisition of Wyeth could swing the company back to a diversified portfolio - including the return of a consumer health division -and help offset a dwindling pipeline and the looming generic competition that threatens Rx sales, analysts say
Advertisement

Related Content

Sanofi-Aventis Acquisitions Could Double OTC Sales By 2014
Sanofi-Aventis Acquisitions Could Double OTC Sales By 2014
Sanofi-Aventis Acquisitions Could Double OTC Sales By 2014
P&G Focuses On Consumer Health, “Deemphasizes” Pharma
Pfizer Pulls Back On European Viagra Switch As Questions Linger
Sales & Earnings In Brief
J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off
J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off

Topics

Advertisement
UsernamePublicRestriction

Register

PS102543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel